Plasma Carcinoembryonic Antigen In Renal Cell Carcinoma Patients

Chu, T. Ming; Shukla, Satish; Mittleman, Arnold; Murphy, Gerald P.

doi:10.1016/s0022-5347(17)60060-0

Cited by 29 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have been performed with the aim of developing a biomarker with a high predictive value in renal tumors. Chu et al found an overall increase of plasma CEA in 56% of the 23 patients studied ( 11 ), while Guinan et al found similar (41%) CEA positivity in their 23 patients with renal-cell carcinoma ( 12 ). Cases et al (1991) showed that CEA, CA-50 and CA-125 levels were elevated in serum of patients with chronic renal failure and in haemodialysis patients ( 13 ).…”

Section: Discussionmentioning

confidence: 90%

“…CEA serum levels are known to be elevated in patients with a variety of neoplasms derived from the endoderm and ectoderm. Another studies showed CEA levels increased in renal cancer ( 11 - 13 ).…”

Section: Introductionmentioning

confidence: 95%

“…In 2012, there were ~337.000 new cases of RCC diagnosed worldwide with an estimated 143.000 deaths, with the highest incidence and mortality in North America and Europe ( 10 ). Several studies have been performed with the aim of developing a biomarker with a high predictive value in renal tumors ( 11 - 13 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The diagnostic value of FNDC5/Irisin in renal Cell Cancer

et al. 2018

View full text Add to dashboard Cite

Purposes:The aim of this study was to determine the diagnostic significance of fibronectin type III domain containing protein 5 (FNDC5)/Irisin levels in the sera of patients with renal cell cancer.Materials and Methods:In the study, 48 individuals were evaluated. The patient group included 23 subjects diagnosed with renal tumor, and the control group of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected and serum FNDC5/Irisin and carcinoembryonic antigen (CEA) levels were determined using enzyme-linked immunosorbent assay (ELISA).Results:FNDC5/irisin and CEA levels in renal cancer patients were significantly higher compared with the control group (p=0.0001, p=0.009, respectively). Also, FNDC5 levels was more sensitive and specific than CEA levels. The best cut-off points for FNDC5/irisin were >105pg/mL and CEA were >2.67ng/mL for renal cancer.Conclusions:FNDC5/Irisin may be used as a diagnostic biomarker for renal cancer.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

The diagnostic value of FNDC5/Irisin in renal Cell Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Some acute phase reactant proteins as well as carcinoembryotic anti gen, renin and erythropoietin have been investigated, none of them being specific [18][19][20][21][22][23][24]. Takashi [8] intro duced y-enolase as a tumor marker in renal cell carcino ma.…”

Section: Discussionmentioning

confidence: 99%

Neuron-Specific Enolase: A Serum Tumor Marker in Renal Cell Carcinoma?

Gross

Michl²,

Bornhöft³

et al. 1993

Eur Urol

View full text Add to dashboard Cite

“…However, there are no known accurate tumor markers that are specific enough for diagnosis or monitoring the postoperative course of the patients with RCC. C-reactive protein [2], lipid-associated sialic acid [3], carcinoembryonic antigen [4], renin, haptoglobulins [5], plasma fibrinogen [6] and erythropoietin [7] are some of the proposed biological markers. Ferritin is one of the major proteins of iron metabolism which is demonstrated to be elevated in the serum of patients with RCC and is suggested as a serum marker [8,9].…”

mentioning

confidence: 99%

Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume

Kırkalı¹,

Güzelsoy²,

Mungan³

et al. 1999

Urol Int

View full text Add to dashboard Cite

Objectives: There is no established tumor marker for renal cell carcinoma (RCC). Ferritin is shown to be expressed by the tumor, and proposed as a tumor marker. The aim of this study is to assess the relation between ferritin levels and tumor volume, size and prognosis in RCC. Methods: We studied ferritin levels in serum from peripheral and renal veins of 52 patients with RCC who underwent surgery. Ferritin levels were measured by an enzyme immunoassay method. Tumor volume and the largest tumor diameter were calculated from the pathologic specimens. Results: The mean serum ferritin level from the renal vein (RVF) was statistically higher than the ferritin level from the peripheral vein (PVF) (p = 0.028). Although mean RVF level increased with increasing stage, it was not significant. While there was a correlation with tumor size, volume and RVF, PVF was in correlation with disease status. PVF in patients with metastatic and/or locally advanced disease was significantly higher than the patients with localized disease (p = 0.023). The initial RVF and PVF levels were predictive of survival (p = 0.028 and p = 0.034, respectively). Conclusions: Higher levels in the renal vein, its positive correlation with tumor size and volume suggest that ferritin is expressed by RCC. Initial peripheral serum values of ferritin can be indicative of disease status and also be a prognosticator of survival.

show abstract

Plasma Carcinoembryonic Antigen In Renal Cell Carcinoma Patients

Cited by 29 publications

References 9 publications

The diagnostic value of FNDC5/Irisin in renal Cell Cancer

The diagnostic value of FNDC5/Irisin in renal Cell Cancer

Neuron-Specific Enolase: A Serum Tumor Marker in Renal Cell Carcinoma?

Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume

Contact Info

Product

Resources

About